Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

March 2 Quick Takes: MorphoSys laying off staff, ending preclinical work

Plus: Flamingo teaming up with Dynacure and updates from Debiopharm, Aldeyra, Checkpoint and more

March 3, 2023 1:08 AM UTC

Taking steps to “optimize its cost structure,” MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will lay off 17% of its staff and discontinue all of its preclinical research programs, with the goal of supporting its mid-to-late stage pipeline. The decision comes about nine months after the biotech offloaded two clinical immunology programs to venture-backed Human Immunology Biosciences Inc. — informally, HI-Bio. MorphoSys, which had more than €1 billion ($1.1 billion) in cash at Sept. 30, said it will “explore other options” for the preclinical programs.

Belgium’s Flamingo Therapeutics Inc. and France’s Dynacure S.A.S. will merge to create an oncology company focused on Flamingo’s danvatirsen, an antisense oligonucleotide targeting STAT3 that is in Phase II testing for head and neck cancer, and FTX-001, an IND-ready long non-coding RNA therapy targeting MALAT 1 for solid tumors. The combined company will retain Flamingo’s name and be led by Dynacure CEO Stéphane van Rooijen  as CEO and Flamingo CEO Michael Garrett, who will be COO. Flamingo investors Kurma Partners and PMV made an undisclosed investment in the company. Financial terms of the merger were not disclosed...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article